Search research articles
Contact Us
Filters
Showing results (51-60 of 199) with videos related to
Page
of 20
Sort By:
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
January 23, 2013
Targeting and killing of metastatic cells in the transgenic adenocarcinoma of mouse prostate model with vesicular stomatitis virus
Maryam Moussavi, Howard Tearle, Ladan Fazli, et al.
Cytokine & Growth Factor Reviews
|
March 27, 2010
Double trouble for tumours: exploiting the tumour microenvironment to enhance anticancer effect of oncolytic viruses
Naomi De Silva, Harold Atkins, David H Kirn, et al.
Cancer Cell International
|
June 19, 2012
Enhanced vesicular stomatitis virus (VSVΔ51) targeting of head and neck cancer in combination with radiation therapy or ZD6126 vascular disrupting agent
Nehad M Alajez, Joseph D Mocanu, Tiffany Krushel, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
December 24, 2009
Intelligent design: combination therapy with oncolytic viruses
Kathryn Ottolino-Perry, Jean-Simon Diallo, Brian D Lichty, et al.
Analytical Chemistry
|
January 17, 2012
Electrochemical sensing of aptamer-facilitated virus immunoshielding
Mahmoud Labib, Anna S Zamay, Darija Muharemagic, et al.
Analytical Chemistry
|
October 11, 2012
Viral quantitative capillary electrophoresis for counting and quality control of RNA viruses
Afnan Azizi, Gleb G Mironov, Darija Muharemagic, et al.
Analytical Chemistry
|
February 14, 2012
Electrochemical differentiation of epitope-specific aptamers
Mahmoud Labib, Anna S Zamay, Darija Muharemagic, et al.
Nature Reviews. Cancer
|
April 27, 2018
Oncolytic viruses as engineering platforms for combination immunotherapy
Kwame Twumasi-Boateng, Jessica L Pettigrew, Y Y Eunice Kwok, et al.
Journal of the American Chemical Society
|
September 29, 2012
Anti-Fab aptamers for shielding virus from neutralizing antibodies
Darija Muharemagic, Mahmoud Labib, Shahrokh M Ghobadloo, et al.
Current Opinion in Virology
|
April 23, 2015
Pexa-Vec double agent engineered vaccinia: oncolytic and active immunotherapeutic
Caroline J Breitbach, Kelley Parato, James Burke, et al.
Page
of 20
Search research articles
Search
Showing results (51-60 of 199) with videos related to
Sort By:
Page
of 20
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
January 23, 2013
Targeting and killing of metastatic cells in the transgenic adenocarcinoma of mouse prostate model with vesicular stomatitis virus
Maryam Moussavi, Howard Tearle, Ladan Fazli, et al.
Cytokine & Growth Factor Reviews
|
March 27, 2010
Double trouble for tumours: exploiting the tumour microenvironment to enhance anticancer effect of oncolytic viruses
Naomi De Silva, Harold Atkins, David H Kirn, et al.
Cancer Cell International
|
June 19, 2012
Enhanced vesicular stomatitis virus (VSVΔ51) targeting of head and neck cancer in combination with radiation therapy or ZD6126 vascular disrupting agent
Nehad M Alajez, Joseph D Mocanu, Tiffany Krushel, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
December 24, 2009
Intelligent design: combination therapy with oncolytic viruses
Kathryn Ottolino-Perry, Jean-Simon Diallo, Brian D Lichty, et al.
Analytical Chemistry
|
January 17, 2012
Electrochemical sensing of aptamer-facilitated virus immunoshielding
Mahmoud Labib, Anna S Zamay, Darija Muharemagic, et al.
Analytical Chemistry
|
October 11, 2012
Viral quantitative capillary electrophoresis for counting and quality control of RNA viruses
Afnan Azizi, Gleb G Mironov, Darija Muharemagic, et al.
Analytical Chemistry
|
February 14, 2012
Electrochemical differentiation of epitope-specific aptamers
Mahmoud Labib, Anna S Zamay, Darija Muharemagic, et al.
Nature Reviews. Cancer
|
April 27, 2018
Oncolytic viruses as engineering platforms for combination immunotherapy
Kwame Twumasi-Boateng, Jessica L Pettigrew, Y Y Eunice Kwok, et al.
Journal of the American Chemical Society
|
September 29, 2012
Anti-Fab aptamers for shielding virus from neutralizing antibodies
Darija Muharemagic, Mahmoud Labib, Shahrokh M Ghobadloo, et al.
Current Opinion in Virology
|
April 23, 2015
Pexa-Vec double agent engineered vaccinia: oncolytic and active immunotherapeutic
Caroline J Breitbach, Kelley Parato, James Burke, et al.
Page
of 20